Matthew J. Ellis

65.5k citations

321 papers · 26.9k indexed · 13 hit papers · h-index 65

Oncology top 0.02%
Cancer Research top 0.01%
Molecular Biology top 0.5%
Pulmonary and Respiratory Medicine top 0.1%
Genetics top 0.1%

Co-authors: Charles M. Perou Daniel F. Hayes X. Cynthia G. Thomas Budd Gerald V. Doyle Massimo Cristofanilli Joel S. Parker Michael Craig Miller
Topics: Breast Cancer Treatment Studies (115 papers)Estrogen and related hormone effects (91 papers)HER2/EGFR in Cancer Research (83 papers)
Cited by: Cancer Research Oncology Pulmonary and Respiratory Medicine
Journals: Nature New England Journal of Medicine Proceedings of the National Academy of Sciences
Partner nations: United States Canada United Kingdom

In The Last Decade

Matthew J. Ellis

309 papers receiving 26.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer

2004 3.5k citations Matthew J. Ellis, Daniel F. Hayes et al. profile →
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

2009 3.1k citations Joel S. Parker, Maggie C.U. Cheang et al. Journal of Clinical Oncology profile →
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

2009 1.6k citations Maggie C.U. Cheang, Stephen Chia et al. profile →
CDK4/6 inhibition triggers anti-tumour immunity

2017 998 citations Jeremy Hoog, Matthew J. Ellis et al. profile →
Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival

2006 808 citations Daniel F. Hayes, Matthew J. Ellis et al. Clinical Cancer Research profile →
Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial

2001 790 citations Matthew J. Ellis et al. Journal of Clinical Oncology profile →
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

2012 600 citations Shyam M. Kavuri, Shunqiang Li et al. Cancer Discovery profile →
Long noncoding RNA MALAT1 suppresses breast cancer metastasis

2018 546 citations Matthew J. Ellis et al. profile →
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer

2010 542 citations Torsten O. Nielsen, Joel S. Parker et al. Clinical Cancer Research profile →
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

2001 530 citations Matthew J. Ellis et al. profile →
Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

2005 503 citations Matthew J. Ellis et al. Journal of Clinical Oncology profile →
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

2015 458 citations Matthew J. Ellis, Lisa A. Carey et al. profile →
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

2016 384 citations Matthew J. Ellis et al. profile →

Peers

Countries citing papers authored by Matthew J. Ellis

Since Specialization

Citations

This map shows the geographic impact of Matthew J. Ellis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew J. Ellis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew J. Ellis more than expected).

Fields of papers citing papers by Matthew J. Ellis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew J. Ellis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew J. Ellis. The network helps show where Matthew J. Ellis may publish in the future.

Co-authorship network of co-authors of Matthew J. Ellis

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew J. Ellis. A scholar is included among the top collaborators of Matthew J. Ellis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew J. Ellis. Matthew J. Ellis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association of Age and Gender With Concerns About Live Donor Kidney Transplantation Among Black Individuals 2023 ·Transplantation Proceedings ·(unknown),Patti L. Ephraim,Clemontina A. Davenport,Lisa M. McElroy,Dinushika Mohottige,Nicole DePasquale,Joseph Lunyera,Tara S. Strigo,(unknown),(unknown),(unknown),Matthew J. Ellis,L. Ebony Boulware	1
2	Deep learning segmentation of glomeruli on kidney donor frozen sections 2021 ·Journal of Medical Imaging ·Xiang Li,Richard Davis,(unknown),Zehan Wang,(unknown),(unknown),Jonathan Bell,Matthew J. Ellis,David N. Howell,Xiling Shen,Kyle J. Lafata,Laura Barisoni	16
3	ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106. 2020 ·Journal of Clinical Oncology ·X. Cynthia,Vera J. Suman,A. Marilyn Leitch,Souzan Sanati,Kiran Vij,Gary Unzeitig,Jeremy Hoog,Mark A. Watson,Olwen Hahn,J. Michael Guenther,Abigail S. Caudle,Travis Dockter,Larissa A. Korde,Anna Weiss,Kelly K. Hunt,Clifford A. Hudis,Eric P. Winer,Ann H. Partridge,Lisa A. Carey,Matthew J. Ellis,(unknown)	27
4	Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers 2018 ·Clinical Cancer Research ·Meenakshi Anurag,(unknown),Jeremy Hoog,Matthew N. Bainbridge,Matthew J. Ellis,Svasti Haricharan	57
5	FGFR1-Activated Translation of WNT Pathway Components with Structured 5′ UTRs Is Vulnerable to Inhibition of EIF4A-Dependent Translation Initiation 2018 ·Cancer Research ·Tuan M. Nguyen,Elena B. Kabotyanski,Yongchao Dou,Lucas C. Reineke,Peng Zhang,Xiang H.-F. Zhang,Anna Malovannaya,Sung Yun Jung,Qianxing Mo,Kevin Roarty,Yiwen Chen,Bing Zhang,Joel R. Neilson,Richard E. Lloyd,Charles M. Perou,Matthew J. Ellis,Jeffrey M. Rosen	19
6	Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer 2017 ·Clinical Cancer Research ·Iman Doostan,Cansu Karakaş,(unknown),(unknown),Matthew J. Ellis,John A. Olson,Vera J. Suman,Kelly K. Hunt,Stacy Moulder,Khandan Keyomarsi	35
7	Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer 2017 ·Cancer Discovery ·Svasti Haricharan,(unknown),Purba Singh,Kimberly R. Holloway,Meenakshi Anurag,(unknown),(unknown),Jonathan T. Lei,Vera J. Suman,Kelly K. Hunt,John A. Olson,Jeremy Hoog,Shunqiang Li,Shixia Huang,Dean P. Edwards,Shyam M. Kavuri,Matthew N. Bainbridge,X. Cynthia,Matthew J. Ellis	50
8	Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer 2016 ·Molecular Cancer Therapeutics ·Jianfeng Lü,Donna McEachern,Shunqiang Li,Matthew J. Ellis,Shaomeng Wang	30
9	A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer 2016 ·Clinical Cancer Research ·X. Cynthia,César Sánchez,Feng Gao,Robert J. Crowder,Michael Naughton,Timothy Pluard,(unknown),Zhanfang Guo,Jeremy Hoog,A. Craig Lockhart,Austin Doyle,Charles Erlichman,Matthew J. Ellis	62
10	Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy 2016 ·Cancer Research ·James N. Ingle,Fang Xie,Matthew J. Ellis,Paul E. Goss,Lois E. Shepherd,J. W. Chapman,Bingshu E. Chen,Michiaki Kubo,Yoichi Furukawa,Yukihide Momozawa,Vered Stearns,Kathleen I. Pritchard,Poulami Barman,Erin E. Carlson,Matthew P. Goetz,Richard M. Weinshilboum,Krishna R. Kalari,Liewei Wang	43
11	Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer 2015 ·Clinical Cancer Research ·Suzanne E. Wardell,Matthew J. Ellis,Holly M. Alley,(unknown),Todd VanArsdale,Stephen G. Dann,Kim Arndt,Tina Primeau,Elizabeth Griffin,Jieya Shao,Robert G. Crowder,Jinping Lai,John D. Norris,Donald P. McDonnell,Shunqiang Li	115
12	A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer 2015 ·Clinical Cancer Research ·X. Cynthia,Jingqin Luo,Michael Naughton,Foluso O. Ademuyiwa,Rama Suresh,Malachi Griffith,Obi L. Griffith,Zachary L. Skidmore,Nicholas C. Spies,Avinash Ramu,Lee Trani,Timothy Pluard,Gayathri Nagaraj,Shana Thomas,Zhanfang Guo,Jeremy Hoog,Jing Han,Elaine R. Mardis,(unknown),Matthew J. Ellis	77
13	Safety and Preliminary Evidence of Biologic Efficacy of a Mammaglobin-A DNA Vaccine in Patients with Stable Metastatic Breast Cancer 2014 ·Clinical Cancer Research ·Venkataswarup Tiriveedhi,(unknown),John M. Herndon,Lijin Li,Mark Sturmoski,Matthew J. Ellis,X. Cynthia,Michael Naughton,A. Craig Lockhart,Feng Gao,Timothy P. Fleming,Peter S. Goedegebuure,Thalachallour Mohanakumar,William E. Gillanders	75
14	Combined Targeting of mTOR and AKT Is an Effective Strategy for Basal-like Breast Cancer in Patient-Derived Xenograft Models 2013 ·Molecular Cancer Therapeutics ·Siguang Xu,Shunqiang Li,Zhanfang Guo,Jingqin Luo,Matthew J. Ellis,X. Cynthia	41
15	A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen 2012 ·Clinical Cancer Research ·Stephen Chia,Vivien Bramwell,Dongsheng Tu,Lois E. Shepherd,Shan Jiang,Tammi L. Vickery,Elaine R. Mardis,Samuel Leung,Karen Ung,Kathleen I. Pritchard,Joel S. Parker,Philip S. Bernard,Charles M. Perou,Matthew J. Ellis,Torsten O. Nielsen	220
16	Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial 2012 ·Clinical Cancer Research ·Maggie C.U. Cheang,K. David Voduc,Dongsheng Tu,Shan Jiang,Samuel Leung,Stephen Chia,Lois E. Shepherd,Mark N. Levine,Kathleen I. Pritchard,Sherri R. Davies,Inge J. Stijleman,Carole Davis,Mark Ebbert,Joel S. Parker,Matthew J. Ellis,Philip S. Bernard,Charles M. Perou,Torsten O. Nielsen	105
17	Opposing Effects of Runx2 and Estradiol on Breast Cancer Cell Proliferation: In Vitro Identification of Reciprocally Regulated Gene Signature Related to Clinical Letrozole Responsiveness 2011 ·Clinical Cancer Research ·Nyam-Osor Chimge,Sanjeev K. Baniwal,Jingqin Luo,Simon G. Coetzee,Omar Khalid,Benjamin P. Berman,Debu Tripathy,Matthew J. Ellis,Baruch Frenkel	39
18	A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancerbreakdown → 2010 ·Clinical Cancer Research ·Torsten O. Nielsen,Joel S. Parker,Samuel Leung,D. Voduc,Mark Ebbert,Tammi L. Vickery,Sherri R. Davies,Jacqueline Snider,Inge J. Stijleman,Jerry P. Reed,Maggie C.U. Cheang,Elaine R. Mardis,Charles M. Perou,Philip S. Bernard,Matthew J. Ellis	542
19	PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor–Positive Breast Cancer 2009 ·Cancer Research ·Robert J. Crowder,Chanpheng Phommaly,Tao Yu,Jeremy Hoog,Jingqin Luo,Charles M. Perou,Joel S. Parker,Melinda A. Miller,David G. Huntsman,Lin Li,Jacqueline Snider,Sherri R. Davies,John A. Olson,Mark A. Watson,Anthony J. Saporita,Jason D. Weber,Matthew J. Ellis	174
20	Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 2006 ·Breast Cancer Research ·Lyndsay N. Harris,Gloria Broadwater,Nancy U. Lin,Alexander Miron,Stuart J. Schnitt,David P. Cowan,Jonathan F. Lara,Ira J. Bleiweiss,Donald A. Berry,Matthew J. Ellis,Daniel F. Hayes,Eric P. Winer,Lynn Dressler	123

About Matthew J. Ellis

Matthew J. Ellis is a scholar working on Cancer Research, Oncology and Transplantation, having authored 321 papers that have together received 26.9k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (115 papers), Estrogen and related hormone effects (91 papers) and HER2/EGFR in Cancer Research (83 papers). The work is most often cited by research in Cancer Research (13.1k citations), Oncology (15.9k citations) and Pulmonary and Respiratory Medicine (6.7k citations). Matthew J. Ellis has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Charles M. Perou, Daniel F. Hayes, X. Cynthia, G. Thomas Budd, Gerald V. Doyle, Massimo Cristofanilli, Joel S. Parker, Michael Craig Miller, W. Jeffrey Allard and Jeri Matera. Their work appears in journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact